IVACC — Intervacc AB Share News
0.000.00%
Last trade - 00:00- SEK265.15m
- SEK138.38m
- SEK20.09m
Brief: Intervacc Q1 Operating Loss Widens To SEK 18 Mln
Brief: Intervacc Jonas Sohlman As New CEO
Brief: Intervacc's Vaccine Gets U.S. Patent Approval
Brief: Intervacc 9M Sales SEK 6.4 Million
Brief: Intervacc Q2 Oper Loss Widens To SEK 18.4 Mln
Brief: Intervacc H1 Operating Profit at SEK -35.8 Million
Brief: Andreas Andersson Steps Down As President, CEO Of Intervacc
Brief: Intervacc Gets Grant From Vinnova
Brief: Intervacc To Collaborate With Testa Center To Optimise Production Processes
Brief: Intervacc Announces The Outcome Of The Fully Secured Rights Issue
Brief: Intervacc Says EMA Approves Extention Of Shelf Life For Strangvac To 33 Months
Brief: Intervacc Has Resolved On A Fully Covered Rights Issue Of Approximately SEK 104 Mln
Brief: Intervacc Q1 Operating Profit at SEK -17.4 Million
Brief: Intervacc To Resolve On Rights Issue Of SEK 100 Million
Brief: Intervacc Q4 Operating Loss Sek 23.4 Million
Brief: Intervacc, SLU Extend Multi-Year Contract For The Development Of Innovative Animal Health Vaccines
Brief: Intervacc Q3 Operating Loss Widens To SEK 14.6 Mln
Brief: Intervacc's Strangvac Released For Sales In Germany, France, Austria And The Benelux
Brief: Intervacc Q2 Operating Loss Widens To SEK 15.7 Mln